Tag Archives: QALY

UK: Patient Group Sets Out Orphan Drug Charter

By Leela Barham. There has been a lot of concern about the decision to give the National Institute for Health and Care Excellence (NICE) the responsibility to look at “highly specialized technologies” (HSTs, or orphan drugs to you and me). That decision was taken just as the NHS across England was going through major reform […]
Posted in Europe, Global, Guest Blog, healthcare, Op-Ed, Orphan Drugs, Patient Communication, patient education, pricing, Regulatory | Also tagged , , , , , , , | Leave a comment

Pursuing the 'Real' Cost Effectiveness Threshold in England

By Leela Barham. The Incremental Cost Effectiveness Ratio (ICER) thresholds used by agencies such as the UK’s National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and as far afield as Australia by the Pharmaceutical Benefits Advisory Committee (PBAC) are often controversial. This is mostly because it means analysts saying that a […]
Posted in Europe, Guest Blog, Op-Ed, pricing | Also tagged , , , , , , , , , | Leave a comment

New Roster of Players to Debate Comparative Effectiveness Standards

Methodologies are the heart of any consistent approach to certifying comparative effectiveness for new medicines—semantics aside, it’s the way payers and providers are going to determine clinical “value” and, by subtle extrapolation, their cost against existing alternative therapies. Last week, the Patient Centered Outcomes Research Institute [PCORI] created through federal health reform legislation moved one […]
Posted in healthcare, People, pricing, Regulatory | Also tagged , , | Leave a comment
  • Categories

  • Meta